Oculogenex is a biopharmaceutical company based in La Habra, California, established in 2020. The company specializes in developing gene therapies specifically aimed at treating retinal disorders. Its innovative approach involves ocular regenerative gene therapy that protects retinal pigment epithelial cells from oxidative stress-induced damage, which is a contributing factor to macular degeneration. By focusing on these therapies, Oculogenex aims to enhance the detection and treatment of various retinal disorders, ultimately supporting researchers in advancing novel drug solutions in this critical area of healthcare.
NovoClade is a synthetic biology company focused on developing environmentally friendly solutions for insect control and invasive species eradication. The company utilizes gene-editing technology to create sterile mosquito populations, aiming to mitigate the spread of diseases carried by these insects. By offering chemical-free pest control alternatives, NovoClade provides clients with innovative formulas that effectively reduce disease transmission without harming the environment. Through their advancements in genetic bio-control, NovoClade addresses critical public health challenges while promoting sustainable practices in pest management.
Ezrabio is a biotechnology company that specializes in RNA adenylation technology, facilitating ribosome profiling across diverse biological samples. By offering rapid cDNA library construction and streamlined services from sample preparation to deep sequencing, Ezrabio empowers researchers and medical professionals to uncover hidden coding potential, analyze translational responses, identify tumor-associated antigens, and inform mRNA therapeutics. Their innovative approach simplifies complex processes, making it easier for scientists to conduct critical research in genetics and molecular biology.
Acrigen Biosciences focuses on enhancing the safety and efficacy of gene editing technologies, particularly those based on the CRISPR-Cas system. Founded in 2019 and headquartered in Berkeley, California, the company develops innovative solutions that aim to produce effective in vivo drug therapies to combat various diseases. Acrigen's proprietary technologies include Acro proteins that regulate the CRISPR-Cas gene editing process and an advanced bioinformatics discovery software platform that identifies suitable CRISPR systems for human therapeutic applications. Through these advancements, Acrigen Biosciences seeks to improve the precision, efficacy, and safety of genetic therapies, ultimately contributing to the potential prevention and cure of debilitating diseases.
DNALite Therapeutics, Inc. is a biopharmaceutical company focused on developing gene therapy treatments specifically for the gastrointestinal tract. Founded in 2016 and based in San Francisco, California, the company utilizes proprietary technology to deliver therapeutic DNA directly to intestinal stem cells, aiming to address the underlying causes of diseases such as Familial Adenomatous Polyposis (FAP), a hereditary form of colorectal cancer that often necessitates invasive surgical procedures. By targeting these root causes, DNALite seeks to prevent disease progression rather than merely managing symptoms, offering a potentially transformative approach to treating gastrointestinal disorders, including colorectal cancer and Crohn's disease.
Synvivia makes ON-OFF switches for genetically engineered organisms. These protein switches are controlled by small molecules. By installing these switches into an organism, Synvivia creates engineered organisms that can be controlled with small molecules.
Developer of a novel approach augmented low-pass long-read NGS designed to facilitate the detection of complex genetic variation. The company's platform processes long-read ngs raw data DNA sequences, enabling clients to minimize time spent on variant calling and have resolved variants, with a reduction of cost, and improved tat and scalability.
Stellate DNA, founded in 2020 and headquartered in Cambridge, Massachusetts, specializes in developing proprietary DNA donor technology for the synthesis and production of single-strand DNA donors. The company employs a clonal synthesis approach rather than traditional chemical methods, allowing for the manufacture of customizable gene knock-in payloads. This platform enables production at microgram to milligram scales while maintaining controlled costs, thereby assisting medical professionals in achieving minimal mutation rates and ensuring sequence uniformity.
Tacit Therapeutics is a biotechnology company focused on developing RNA-targeted treatments to address genetic diseases. Founded in 2021 and based in South San Francisco, California, the company utilizes pre-existing components of human cells to create innovative, non-immunogenic methods for repairing mutated genes. By offering a broadly applicable approach to gene modification, Tacit Therapeutics aims to provide effective solutions for genetic conditions that were previously deemed untreatable, thereby enabling advancements in the treatment of devastating diseases.
Oculogenex is a biopharmaceutical company based in La Habra, California, established in 2020. The company specializes in developing gene therapies specifically aimed at treating retinal disorders. Its innovative approach involves ocular regenerative gene therapy that protects retinal pigment epithelial cells from oxidative stress-induced damage, which is a contributing factor to macular degeneration. By focusing on these therapies, Oculogenex aims to enhance the detection and treatment of various retinal disorders, ultimately supporting researchers in advancing novel drug solutions in this critical area of healthcare.
Ansa Biotechnologies, Inc. is a biotechnology company based in Berkeley, California, focused on developing innovative DNA synthesis technology utilizing enzymes. Established in 2018, the company aims to improve upon traditional chemical methods of DNA synthesis that have remained largely unchanged for decades. Ansa's enzymatic approach offers significant advantages, including increased speed, accuracy, and cleanliness in the production of DNA fragments such as oligonucleotides. This technology enhances the capabilities of biological research, therapeutics, diagnostics, and biomanufacturing by enabling the synthesis of gene-length oligonucleotides. Through its advancements, Ansa Biotechnologies seeks to facilitate innovation in the fields of biological research and engineering, ultimately providing valuable services to medical researchers and contributing to the broader biotechnology landscape.
Cobio Diagnostics is a biotechnology company that develops diagnostics for bacterial identification and phenotypic antibiotic resistance testing. The company was established in 2016 and is based in Golden, Colorado.
CasTag Biosciences specializes in cell biology and regenerative medicine, focusing on revolutionizing the speed of endogenously protein analysis. The company aims to accelerate scientific discovery by offering tools that allow scientists to study novel genes in any experimental model.
Developer of RNA therapies designed to inoculate trees, vines, and bushes against diseases, eliminating the need for genetic modification. The company's RNA therapy includes introducing a virus like RNA bacterial inside the tree veins to destroy viral and fungal pathogens, enabling food growers to ensure abundant and diverse food supplies while protecting natural resources.
Cornerstone Genomics offers advice on the use of genomic tools in human disease and biomedicine, veterinary sciences, and wildlife research. The company was founded in 2017 and is headquartered in Frederick, Maryland.
Seven Biosciences provides drug discovery platforms for G-protein coupled receptors. The company, based in Davis, California, was founded by Grace Mizuno and Lin Tian.
GRO Biosciences is leveraging breakthrough technologies from computational protein design and synthetic biology to develop best-in-class protein therapeutics with enhanced properties. The company has established multiple genomically recoded strains of bacteria that can incorporate non-standard amino acids into proteins to confer increased potency, stability, and targeted delivery. GRO Biosciences is applying its technology platform to develop improved protein therapeutics for diabetes, growth disorders and autoimmunity. The company, co-founded by Dr. George Church, is located at the Harvard Life Lab, a shared laboratory space for high-potential life sciences and biotechnology startups founded by Harvard faculty, alumni, students, and postdoctoral scholars.
Inherent Biosciences is a molecular diagnostics company that revolutionizes trial and error medicine and restore hope. The company does this by discovering what's inherent in our biology about the unexplained and translating discoveries into personal insights that inform actions. Inherent Biosciences develops medicines for treating pain, infertility, embryo quality, autism, rheumatoid arthritis, psoriatic arthritis, fetal heart disease, COVID-19, and many more.
Acrigen Biosciences focuses on enhancing the safety and efficacy of gene editing technologies, particularly those based on the CRISPR-Cas system. Founded in 2019 and headquartered in Berkeley, California, the company develops innovative solutions that aim to produce effective in vivo drug therapies to combat various diseases. Acrigen's proprietary technologies include Acro proteins that regulate the CRISPR-Cas gene editing process and an advanced bioinformatics discovery software platform that identifies suitable CRISPR systems for human therapeutic applications. Through these advancements, Acrigen Biosciences seeks to improve the precision, efficacy, and safety of genetic therapies, ultimately contributing to the potential prevention and cure of debilitating diseases.
A-Alpha Bio, Inc., founded in 2017 and based in Seattle, Washington, specializes in synthetic biology with a focus on drug development that targets multiple proteins. The company's flagship platform, AlphaSeq, offers innovative cell-based tools for quantitative and high-throughput measurement of protein interactions. This technology accelerates processes such as target discovery, library screening, and preclinical drug characterization, addressing significant bottlenecks in the industry. By providing biologics and molecular glue discovery and optimization services, A-Alpha Bio supports pharmaceutical companies in enhancing binding and specificity for various target proteins. The team comprises experts in synthetic biology, structural biology, and next-generation sequencing, all dedicated to advancing drug discovery methodologies.
Plastomics Inc. is a biotechnology company based in Saint Louis, Missouri, that specializes in chloroplast genetic engineering to enhance crop performance. Founded in 2016, the company focuses on developing advanced crops through gene stacking and rapid breeding techniques, aimed at improving yield production and nutritional quality. Plastomics' technology platform allows for the precise insertion of beneficial traits into the chloroplasts of plant cells, which helps seed companies create more effective biotech crops. This innovative approach not only eliminates cross-pollination but also enables unique maternal inheritance, thereby reducing both breeding timelines and costs associated with bringing new products to market. Through its efforts, Plastomics addresses various challenges faced by the agricultural industry.
Developer of derived red blood cells intended to leverage natural genetic processes to support healthcare providers and patients in need. The company's platform has created red blood cells by genetically engineering human stem cells, enabling patients at risk to receive blood on demand.
A-Alpha Bio, Inc., founded in 2017 and based in Seattle, Washington, specializes in synthetic biology with a focus on drug development that targets multiple proteins. The company's flagship platform, AlphaSeq, offers innovative cell-based tools for quantitative and high-throughput measurement of protein interactions. This technology accelerates processes such as target discovery, library screening, and preclinical drug characterization, addressing significant bottlenecks in the industry. By providing biologics and molecular glue discovery and optimization services, A-Alpha Bio supports pharmaceutical companies in enhancing binding and specificity for various target proteins. The team comprises experts in synthetic biology, structural biology, and next-generation sequencing, all dedicated to advancing drug discovery methodologies.
Provider of end-to-end molecular surveillance services intended to treat infectious disease dynamics and molecular surveillance of pathogens. The company's services include ribonucleic acid (RNA) and deoxyribonucleic acid (RNA) extraction, genomic sequencing, data analytics, and cloud-based data visualizations., enabling clients to research and develop various tests and avail of proper lab services.
Attogene is a biotechnology company that develops cutting-edge technologies for sensing compounds in a wide range of samples. The company was founded in 2012 and is based in Austin, Texas.
Algenesis is a material science and technology company focused on addressing the environmental challenges posed by fossil fuel-based products. It specializes in manufacturing renewable and biodegradable plastic materials derived from algae. The company develops biodegradable polyurethane foam products, including soft foams suitable for footwear and hard foams designed for surfboards. By creating these innovative materials, Algenesis aims to help businesses tackle the global plastic pollution crisis and promote more sustainable alternatives in various industries.
NovoClade is a synthetic biology company focused on developing environmentally friendly solutions for insect control and invasive species eradication. The company utilizes gene-editing technology to create sterile mosquito populations, aiming to mitigate the spread of diseases carried by these insects. By offering chemical-free pest control alternatives, NovoClade provides clients with innovative formulas that effectively reduce disease transmission without harming the environment. Through their advancements in genetic bio-control, NovoClade addresses critical public health challenges while promoting sustainable practices in pest management.
Parse Biosciences, based in Seattle, Washington, focuses on single-cell analysis and was incorporated in 2018. The company is dedicated to developing innovative technologies that enhance the understanding of cellular diversity and function at the single-cell level. By leveraging advanced methodologies, Parse Biosciences aims to provide researchers with powerful tools for exploring complex biological systems, ultimately advancing the fields of genomics and biomedical research.
Design Therapeutics, Inc. is a clinical-stage biotechnology company based in Solana Beach, California, focused on developing innovative therapies for degenerative disorders resulting from nucleotide repeat expansions. Founded in 2017, the company is advancing its lead program aimed at treating Friedreich's ataxia, while also exploring treatment options for other conditions such as Fragile X syndrome and myotonic dystrophy. Design Therapeutics is known for its GeneTACTM molecules, a new class of small-molecule gene-targeted therapies designed to address the underlying causes of diseases linked to inherited nucleotide repeat expansion mutations. The company's ongoing research efforts seek to develop disease-modifying treatments for serious conditions driven by these genetic factors.
Ansa Biotechnologies, Inc. is a biotechnology company based in Berkeley, California, focused on developing innovative DNA synthesis technology utilizing enzymes. Established in 2018, the company aims to improve upon traditional chemical methods of DNA synthesis that have remained largely unchanged for decades. Ansa's enzymatic approach offers significant advantages, including increased speed, accuracy, and cleanliness in the production of DNA fragments such as oligonucleotides. This technology enhances the capabilities of biological research, therapeutics, diagnostics, and biomanufacturing by enabling the synthesis of gene-length oligonucleotides. Through its advancements, Ansa Biotechnologies seeks to facilitate innovation in the fields of biological research and engineering, ultimately providing valuable services to medical researchers and contributing to the broader biotechnology landscape.
DNALite Therapeutics, Inc. is a biopharmaceutical company focused on developing gene therapy treatments specifically for the gastrointestinal tract. Founded in 2016 and based in San Francisco, California, the company utilizes proprietary technology to deliver therapeutic DNA directly to intestinal stem cells, aiming to address the underlying causes of diseases such as Familial Adenomatous Polyposis (FAP), a hereditary form of colorectal cancer that often necessitates invasive surgical procedures. By targeting these root causes, DNALite seeks to prevent disease progression rather than merely managing symptoms, offering a potentially transformative approach to treating gastrointestinal disorders, including colorectal cancer and Crohn's disease.
Developer of fast-tracking drugs designed to treat genetic diseases with a focus on Huntington's Disease. The company's drugs are discovered through its proprietary human stem cell technology that uses single-cell, time-lapse imaging and customized analytic tools to inexpensively and effectively identify treatments for human genetic diseases, enabling patients to receive improved treatment success rates, speedy drug development, and enhanced outcomes.
GenEdit Inc. is a biotechnology company based in Berkeley, California, established in 2016. It specializes in developing innovative genome editing technologies, particularly using the CRISPR/Cas9 system for therapeutic gene editing. The company focuses on addressing the challenges associated with the delivery of gene therapies through its proprietary non-viral nanoparticle-based delivery platform. This platform enables more efficient and accurate delivery of CRISPR components, enhancing the potential for curative treatments for genetic diseases. By systematically screening a library of nanoparticles, GenEdit aims to improve the safety and effectiveness of gene editing, making it a promising solution for a wide range of therapeutic applications.
GRO Biosciences is leveraging breakthrough technologies from computational protein design and synthetic biology to develop best-in-class protein therapeutics with enhanced properties. The company has established multiple genomically recoded strains of bacteria that can incorporate non-standard amino acids into proteins to confer increased potency, stability, and targeted delivery. GRO Biosciences is applying its technology platform to develop improved protein therapeutics for diabetes, growth disorders and autoimmunity. The company, co-founded by Dr. George Church, is located at the Harvard Life Lab, a shared laboratory space for high-potential life sciences and biotechnology startups founded by Harvard faculty, alumni, students, and postdoctoral scholars.
Cornerstone Genomics offers advice on the use of genomic tools in human disease and biomedicine, veterinary sciences, and wildlife research. The company was founded in 2017 and is headquartered in Frederick, Maryland.
Provider of end-to-end molecular surveillance services intended to treat infectious disease dynamics and molecular surveillance of pathogens. The company's services include ribonucleic acid (RNA) and deoxyribonucleic acid (RNA) extraction, genomic sequencing, data analytics, and cloud-based data visualizations., enabling clients to research and develop various tests and avail of proper lab services.
Novome Biotechnologies, Inc. is a biotechnology company based in South San Francisco, California, that specializes in engineering bacteria from the human gut to address chronic diseases. Founded in 2015, the company has developed a platform for the controlled colonization of the gut with genetically engineered bacteria, known as Genetically Engineered Microbial Medicines (GEMMs). This innovative approach allows for sustained therapeutic interventions through the precise delivery of microbial activities. Novome's lead preclinical program targets hyperoxaluria by creating a therapeutic strain of bacteria aimed at degrading oxalate to help prevent kidney stone formation. The company is also expanding its synthetic biology platform to explore additional therapeutic applications.
A-Alpha Bio, Inc., founded in 2017 and based in Seattle, Washington, specializes in synthetic biology with a focus on drug development that targets multiple proteins. The company's flagship platform, AlphaSeq, offers innovative cell-based tools for quantitative and high-throughput measurement of protein interactions. This technology accelerates processes such as target discovery, library screening, and preclinical drug characterization, addressing significant bottlenecks in the industry. By providing biologics and molecular glue discovery and optimization services, A-Alpha Bio supports pharmaceutical companies in enhancing binding and specificity for various target proteins. The team comprises experts in synthetic biology, structural biology, and next-generation sequencing, all dedicated to advancing drug discovery methodologies.
Algenesis is a material science and technology company focused on addressing the environmental challenges posed by fossil fuel-based products. It specializes in manufacturing renewable and biodegradable plastic materials derived from algae. The company develops biodegradable polyurethane foam products, including soft foams suitable for footwear and hard foams designed for surfboards. By creating these innovative materials, Algenesis aims to help businesses tackle the global plastic pollution crisis and promote more sustainable alternatives in various industries.
Senti Biosciences is a clinical-stage biotechnology company based in South San Francisco, California, focused on developing innovative gene and cell therapies using its proprietary synthetic biology platform. Founded in 2016, the company aims to address complex diseases through advanced therapeutic solutions. Senti's technology includes engineered allogeneic chimeric antigen receptor natural killer (CAR-NK) cells, which are designed to target and eliminate cancer cells while minimizing damage to healthy tissue. Among its product candidates are SENTI-202, a Logic Gated CAR-NK cell therapy intended for cancer treatment, and SENTI-301A, which targets hepatocellular carcinoma. Senti Biosciences operates as a resident company at Johnson & Johnson Innovation's JLABS in South San Francisco, collaborating with experts in synthetic biology and computation to advance its therapeutic developments.
Histogen Inc. is a clinical-stage regenerative medicine company based in San Diego, California, established in 2007. The company specializes in developing therapies using cell products cultivated under simulated embryonic conditions, aiming to stimulate the body's own stem cells. Histogen's product portfolio includes human multipotent cell conditioned media, human extracellular matrix, and hair stimulating complex. The company focuses on creating biologic products that do not involve embryonic stem cells or animal components. Its proprietary technology leverages bioreactors to produce vital proteins and growth factors, leading to the development of two primary product families: a liquid complex of embryonic-like proteins and a human extracellular matrix material called ExCeltrix. Additionally, Histogen is advancing product candidates such as HST-003 for joint cartilage repair and HST-004 for spinal disc repair, along with a pipeline of small molecule inhibitors targeting infectious and inflammatory diseases.
Navipoint Genomics is a bioinformatics analysis software developer that specializes in analyzing entire human genomes. The company was founded in 2015 and is headquartered in Chicago, Illinois.
Varigen Biosciences is developing new technologies for capturing and expressing natural product pathways. Learn about our DNAtrap™ custom cloning service which delivers verified clones of your DNA target (up to 100 kb) in just 10 days at http://varigenbiosciences.com/dnatrap-custom-cloning-service/. Learn about how our BigDNA™ metagenomics libraries can revolutionize natural product discovery at http://varigenbiosciences.com/products/.
enEvolv, Inc. engineers and licenses microorganisms to produce chemicals, enzymes, and small molecules. It offers bacteria, yeast, and algae for various industries, including specialty chemicals, food, energy, personal care, and pharmaceuticals. The company was incorporated in 2011 and is based in Boston, Massachusetts. As of March 18, 2020, enEvolv, Inc. operates as a subsidiary of Zymergen, Inc.
Provider of end-to-end molecular surveillance services intended to treat infectious disease dynamics and molecular surveillance of pathogens. The company's services include ribonucleic acid (RNA) and deoxyribonucleic acid (RNA) extraction, genomic sequencing, data analytics, and cloud-based data visualizations., enabling clients to research and develop various tests and avail of proper lab services.
Novome Biotechnologies, Inc. is a biotechnology company based in South San Francisco, California, that specializes in engineering bacteria from the human gut to address chronic diseases. Founded in 2015, the company has developed a platform for the controlled colonization of the gut with genetically engineered bacteria, known as Genetically Engineered Microbial Medicines (GEMMs). This innovative approach allows for sustained therapeutic interventions through the precise delivery of microbial activities. Novome's lead preclinical program targets hyperoxaluria by creating a therapeutic strain of bacteria aimed at degrading oxalate to help prevent kidney stone formation. The company is also expanding its synthetic biology platform to explore additional therapeutic applications.
Modular Genetics, Inc., a biotechnology company, designs and develops engineered microorganisms that synthesize chemicals using renewable raw materials (sugar). The company was founded in 2000 and is based in Woburn, Massachusetts.
Serotiny, Inc. is a biotechnology company based in San Francisco, California, that specializes in the design and development of multi-domain proteins and therapies aimed at treating cancers and genetic disorders. Founded in 2014, Serotiny utilizes a combination of mammalian synthetic biology and informatics to achieve rational protein design. The company collaborates with leaders in the life sciences to create innovative therapies and tools, tailoring its protein designs to meet specific therapeutic needs.
Conagen is a biotechnology company that focuses on bio-production of ingredients for food, pharmaceutical, and renewable materials industries. Conagen is a discovery-based company. It is passionate about understanding and engineering metabolic pathways. Its scientists are equipped with unprecedented systemic information on cellular metabolism. Its engineers have developed new automation systems and novel fermentation technologies to advance its bio-manufacturing capabilities. The company was founded in 2010 and is headquartered in Bedford, Massachusetts.
Aperiomics, Inc., a biotechnology company, provides pathogens detection services to animal screening, agricultural testing, and human diagnostics industry through a combination of genomics and informatics. The company detects viral, bacterial, fungal, and parasite pathogens in a single test. It uses sequencing technologies and advanced Bayesian statistics to provide results. The company allows its customers’ to send blood, tissue, and stool samples to be sequenced, which then is analyzed through a laboratory using a proprietary informatics pipeline. Aperiomics, Inc. was formerly known as NextGen Diagnostics, Inc. and changed its name to Aperiomics, Inc. in July 2014. The company was founded in 2013 and is based in Sterling, Virginia.
Histogen Inc. is a clinical-stage regenerative medicine company based in San Diego, California, established in 2007. The company specializes in developing therapies using cell products cultivated under simulated embryonic conditions, aiming to stimulate the body's own stem cells. Histogen's product portfolio includes human multipotent cell conditioned media, human extracellular matrix, and hair stimulating complex. The company focuses on creating biologic products that do not involve embryonic stem cells or animal components. Its proprietary technology leverages bioreactors to produce vital proteins and growth factors, leading to the development of two primary product families: a liquid complex of embryonic-like proteins and a human extracellular matrix material called ExCeltrix. Additionally, Histogen is advancing product candidates such as HST-003 for joint cartilage repair and HST-004 for spinal disc repair, along with a pipeline of small molecule inhibitors targeting infectious and inflammatory diseases.
Epicrop Technologies, Inc. is a biotechnology company based in Lincoln, Nebraska, founded in 2013. The company specializes in developing epigenetic technology aimed at enhancing crop yields. Its innovative approach focuses on improving crop development and increasing tolerance to abiotic stress, making it applicable to all plant species. By leveraging this technology, Epicrop enables farmers to boost their crop yields while maintaining lower prices. In addition to its core technology, the company offers support services to optimize crop production.
Knudra Transgenics, LLC researches, develops, and produces deoxyribonucleic acid (DNA) mixes and plasmids for biomedical industry. The company was founded in 2009 and is based in Murray, Utah. Knudra Transgenics, LLC operates as a subsidiary of NemaMetrix, Inc.
Ginkgo Bioworks, founded in 2008 and based in Boston, Massachusetts, specializes in biological engineering by designing, developing, and licensing custom microbes and organisms. The company focuses on discovering and producing a variety of molecules for applications in flavors, sweeteners, cosmetic ingredients, crop treatments, and pharmaceuticals. Additionally, Ginkgo Bioworks offers probiotic bacteria aimed at protecting against harmful infections and creates libraries of molecules for various uses. Its market reach includes sectors such as cultured ingredients, carbon mitigation, probiotics, and natural product discovery.
Nexgen Arrays is a diagnostic technology for detecting Ebola viruses. The company provides a molecular diagnostic platform that enables medical specialists to detect viral diseases such as Ebola, Lassa and Marburg.
enEvolv, Inc. engineers and licenses microorganisms to produce chemicals, enzymes, and small molecules. It offers bacteria, yeast, and algae for various industries, including specialty chemicals, food, energy, personal care, and pharmaceuticals. The company was incorporated in 2011 and is based in Boston, Massachusetts. As of March 18, 2020, enEvolv, Inc. operates as a subsidiary of Zymergen, Inc.
TeselaGen Biotechnology, Inc. is a San Francisco-based company that specializes in developing DNA design and assembly tools aimed at advancing biological research and applications. Founded in 2011, TeselaGen offers a cloud-based platform designed for combinatorial gene design and editing. Its key solutions include a Graphical Sequence Editor for visualizing and annotating gene and plasmid libraries, Symbolic CAD/CAM for constructing novel genetic elements using a comprehensive database, and Fabrication Intelligence that generates optimized protocols for efficient assembly. Additionally, the platform incorporates Validation features to ensure accuracy in aligning sequence traces with design variants. By leveraging artificial intelligence, TeselaGen facilitates rapid prototyping of recombinant molecules and supports large-scale production of DNA assemblies and combinatorial libraries, thereby aiding in the development of therapeutics, high-value chemicals, and agricultural products.
TeselaGen Biotechnology, Inc. is a San Francisco-based company that specializes in developing DNA design and assembly tools aimed at advancing biological research and applications. Founded in 2011, TeselaGen offers a cloud-based platform designed for combinatorial gene design and editing. Its key solutions include a Graphical Sequence Editor for visualizing and annotating gene and plasmid libraries, Symbolic CAD/CAM for constructing novel genetic elements using a comprehensive database, and Fabrication Intelligence that generates optimized protocols for efficient assembly. Additionally, the platform incorporates Validation features to ensure accuracy in aligning sequence traces with design variants. By leveraging artificial intelligence, TeselaGen facilitates rapid prototyping of recombinant molecules and supports large-scale production of DNA assemblies and combinatorial libraries, thereby aiding in the development of therapeutics, high-value chemicals, and agricultural products.
Parabon NanoLabs Inc., a nano-pharmaceutical company, designs and constructs multi-functional macromolecules based on its nanoscale development platform. It develops therapeutics for brain, lung, and breast cancer. The company also develops and licenses its macromolecules for other domain areas, including molecules for nano-sensors for bioweapons defense, nano-arrays for DNA biometrics, and nano-additives for consumer products. In addition, it offers custom nano-design and fabrication services. The company is based in Reston, Virginia. Parabon NanoLabs Inc. operates as a subsidiary of Parabon Computation, Inc.
Aperiomics, Inc., a biotechnology company, provides pathogens detection services to animal screening, agricultural testing, and human diagnostics industry through a combination of genomics and informatics. The company detects viral, bacterial, fungal, and parasite pathogens in a single test. It uses sequencing technologies and advanced Bayesian statistics to provide results. The company allows its customers’ to send blood, tissue, and stool samples to be sequenced, which then is analyzed through a laboratory using a proprietary informatics pipeline. Aperiomics, Inc. was formerly known as NextGen Diagnostics, Inc. and changed its name to Aperiomics, Inc. in July 2014. The company was founded in 2013 and is based in Sterling, Virginia.
Provider of biotechnology products and services intended to back in the detection and inactivation of pathogens including biothreat agents. The company's products and services are based on the aspects of molecular and cellular biology to detect or find traits about hereditary that will assist in future genetic approaches, enabling researchers to research in an enhanced way.
Modular Genetics, Inc., a biotechnology company, designs and develops engineered microorganisms that synthesize chemicals using renewable raw materials (sugar). The company was founded in 2000 and is based in Woburn, Massachusetts.
Molecular Assemblies, Inc. is a San Diego-based company that specializes in enzymatic DNA synthesis technology, which allows for the precise reading and writing of DNA. Founded in 2013, the company targets multiple markets, including life sciences, industrial applications, information storage, nanotechnology, and DNA electronics. Its innovative approach is inspired by natural processes and focuses on producing long, high-quality, sequence-specific DNA in a reliable, affordable, and sustainable manner. The company boasts a strong executive and scientific team and holds an extensive intellectual property portfolio. It has garnered investments from various notable entities, highlighting its potential to advance products in industrial synthetic biology, personalized therapeutics, and precision diagnostics.
The J. Craig Venter Institute is a world leader in genomic research. It was formed in October 2006 through the merger of several affiliated and legacy organizations — The Institute for Genomic Research (TIGR) and The Center for the Advancement of Genomics (TCAG), The J. Craig Venter Science Foundation, The Joint Technology Center, and the Institute for Biological Energy Alternatives (IBEA). Today all these organizations have become one large multidisciplinary genomic-focused organization. With more than 400 scientists and staff, more than 250,000 square feet of laboratory space, and locations in Rockville, Maryland and San Diego, California. For more than two decades Dr. J. Craig Venter and his research teams have been pioneers in genomic research. The revolution began in 1991 when at the National Institutes of Health Dr. Venter and his team developed expressed sequence tags (ESTs), a new technique to rapidly discover genes. Dr. Venter and his colleagues then started a new kind of not for profit research institute, The Institute for Genomic Research (TIGR). With the freedom to pursue any number of exciting avenues in the burgeoning field of genomics, the team decided to use their new computing and computational tools, as well as new DNA sequencing technology, to sequence the first free living organism, Haemophilus influenzae in 1995. With this advance, the floodgates of genomics were opened. TIGR went on to sequence and analyze more than 50 microbial genomes. Dr. Venter and some from his team moved into mammalian genomics and sequenced some of the most important model organisms including the fruit fly, mouse and rat. The world’s attention was perhaps most keenly focused on the sequencing and analysis of one genome — the human — which was published in 2001 by Dr. Venter and his team at Celera Genomics. In the past three years teams have been engaged in some of the most fruitful and exciting research in the biological sciences. We’ve recently published the first diploid human genome and the initial results of our global ocean sampling expedition which uncovered more than six million new genes and thousands of new protein families from organisms found in sea water. Teams have also sequenced the microbial flora found in human environments such as the vagina, oral cavity and human gut. We’re making steady progress in our quest to create a synthetic chromosome and organism having successfully transformed one species of bacteria into another. We’ve also sequenced a variety of important infectious disease agents such as the mosquito species, Aedes aegypti, and we are working to understand the evolution of several viral genomes such as influenza and coronavirus in our quest to help alleviate the scourge of infectious disease around the world.
Caribou Biosciences, Inc. is a biotechnology company based in Berkeley, California, specializing in cellular engineering and genome analysis through CRISPR-Cas9 technology. Founded in 2011, the company provides a gene editing platform that allows for targeted modifications in the genome. Its applications span various sectors, including human and animal therapeutics, agricultural biotechnology, and industrial biotechnology. Caribou's solutions facilitate the development of new disease models, enhance traits in plants, and support functional genomic screens. The company aims to advance both basic and applied biological research, leveraging its transformative capabilities to impact therapeutic development and bioproduction.
enEvolv, Inc. engineers and licenses microorganisms to produce chemicals, enzymes, and small molecules. It offers bacteria, yeast, and algae for various industries, including specialty chemicals, food, energy, personal care, and pharmaceuticals. The company was incorporated in 2011 and is based in Boston, Massachusetts. As of March 18, 2020, enEvolv, Inc. operates as a subsidiary of Zymergen, Inc.
Primordial Genetics Inc. is a biotechnology company based in San Diego, California, established in 2011. It specializes in developing microbes and enzymes for various applications in pharmaceutical and industrial manufacturing, as well as agriculture. The company's core technology, Function Generator, is a combinatorial gain-of-function genetic tool that enhances the tolerances, productivities, and growth characteristics of microbial organisms. This innovative approach enables the rapid development of novel biological products and traits necessary for the microbial production of amino acids, proteins, chemicals, and other valuable compounds. Primordial Genetics' technology has diverse applications, including therapeutic protein and industrial enzyme production, renewable fuels and chemicals, and crop plant enhancements, as well as the discovery and production of natural products and antibiotics.
Digital World Biology develops and sells mobile applications and instructional materials that allow students to conduct molecular biology research. The apps can be used by elementary school students to work with DNA structures and molecules. They bring bioinformatics out of the lab and into the classroom. The company also provides professional development for college instructors and school teachers, as a genomics consulting service.
Ginkgo Bioworks, founded in 2008 and based in Boston, Massachusetts, specializes in biological engineering by designing, developing, and licensing custom microbes and organisms. The company focuses on discovering and producing a variety of molecules for applications in flavors, sweeteners, cosmetic ingredients, crop treatments, and pharmaceuticals. Additionally, Ginkgo Bioworks offers probiotic bacteria aimed at protecting against harmful infections and creates libraries of molecules for various uses. Its market reach includes sectors such as cultured ingredients, carbon mitigation, probiotics, and natural product discovery.
Provider of biotechnology products and services intended to back in the detection and inactivation of pathogens including biothreat agents. The company's products and services are based on the aspects of molecular and cellular biology to detect or find traits about hereditary that will assist in future genetic approaches, enabling researchers to research in an enhanced way.
Modular Genetics, Inc., a biotechnology company, designs and develops engineered microorganisms that synthesize chemicals using renewable raw materials (sugar). The company was founded in 2000 and is based in Woburn, Massachusetts.
Ginkgo Bioworks, founded in 2008 and based in Boston, Massachusetts, specializes in biological engineering by designing, developing, and licensing custom microbes and organisms. The company focuses on discovering and producing a variety of molecules for applications in flavors, sweeteners, cosmetic ingredients, crop treatments, and pharmaceuticals. Additionally, Ginkgo Bioworks offers probiotic bacteria aimed at protecting against harmful infections and creates libraries of molecules for various uses. Its market reach includes sectors such as cultured ingredients, carbon mitigation, probiotics, and natural product discovery.
Cambrian Genomics is a biotechnology company that has developed a novel DNA laser printer, which synthesizes DNA using a laser-based technique. This technology allows the assembly, sequencing, and printing of DNA strands that can be inserted into cells, facilitating the production of genetically modified organisms. Researchers in both academia and industry utilize this innovative system to access high-quality, sequence-verified DNA, contributing to a substantial global market for DNA orders and cloning that exceeds $1 billion annually. By providing a reliable and efficient means of DNA synthesis, Cambrian Genomics supports advancements in genetic research and biotechnological applications.
EnGen Bio, LLC is a development-stage biotechnology company based in Redwood City, California, focused on the discovery and development of vaccines and therapeutic antibodies targeting influenza. The company aims to create a universal vaccine for Type A influenza, leveraging its unique approach to targeting the M1 matrix protein of the virus. EnGen Bio's innovative strategy seeks to provide long-lasting immunity through neutralizing antibody responses in both humans and animals. Established in 2016, the company is actively pursuing opportunities to advance its vaccine and therapeutic candidates, benefiting from significant government funding that supports the development of influenza-related treatments through clinical trials and potential market introduction.
GigaGen is advancing a pipeline of first-in-class biotherapeutics, including novel oncology antibody drug combinations and the world’s first recombinant polyclonal hyperimmune gammaglobulin. Behind our diverse and growing pipeline is a mission to bring forth a new generation of highly efficacious drugs, driven by an unparalleled understanding of immune dysregulation. Our proprietary antibody discovery technology quickly characterizes every cell in complex immune systems, powering our selection of drug targets, identification of drug candidates and preclinical assessment of efficacy.
Akonni Biosystems is a biotechnology company that develops and manufactures, genetic testing devices. Its devices are designed for complex infectious and human health diseases like Methicillin-resistant Staphylococcus aureus (MRSA), multi-drug-resistant tuberculosis (MDR-TB), and influenza sub-typing with oseltamivir-resistance detection.
It was founded in 2003 and headquartered in Maryland, United States.
InnoGenomics Technologies provides genetic testing solutions. That provides DNA quantification, STR genotyping, genotyping and gene expression assays, and other DNA services. They also provide biological sample research and development, validations, and training services.
TeselaGen Biotechnology, Inc. is a San Francisco-based company that specializes in developing DNA design and assembly tools aimed at advancing biological research and applications. Founded in 2011, TeselaGen offers a cloud-based platform designed for combinatorial gene design and editing. Its key solutions include a Graphical Sequence Editor for visualizing and annotating gene and plasmid libraries, Symbolic CAD/CAM for constructing novel genetic elements using a comprehensive database, and Fabrication Intelligence that generates optimized protocols for efficient assembly. Additionally, the platform incorporates Validation features to ensure accuracy in aligning sequence traces with design variants. By leveraging artificial intelligence, TeselaGen facilitates rapid prototyping of recombinant molecules and supports large-scale production of DNA assemblies and combinatorial libraries, thereby aiding in the development of therapeutics, high-value chemicals, and agricultural products.
Knudra Transgenics, LLC researches, develops, and produces deoxyribonucleic acid (DNA) mixes and plasmids for biomedical industry. The company was founded in 2009 and is based in Murray, Utah. Knudra Transgenics, LLC operates as a subsidiary of NemaMetrix, Inc.
Stemgenics, Inc. is a biotechnology company based in Seattle, Washington, specializing in the conversion of mature skin cells into personalized stem cells. Founded in 2008, the company employs a unique process that utilizes patent-pending functionalized nanoparticles to reprogram adult human cells from a small patch of skin into versatile stem cells capable of regenerating various tissues in the human body. These personalized stem cells are designed to be accepted by the body as its own, minimizing the risk of rejection. The applications for Stemgenics' technology include treatments for cancer, eye regeneration, stroke recovery, heart muscle repair, musculoskeletal surgeries, wound healing, hair restoration, and management of liver dysfunction and diabetes. Through its innovative approach, Stemgenics aims to advance regenerative medicine and improve patient outcomes across a range of medical conditions.
Provider of biotech research and reagents intended to serve the life science research community. The company offers DNA Sanger sequencing, gene synthesis, molecular cloning, NGS, hybridoma ab sequencing and lentiviral packaging services.
MOgene LC, a Limited Liability Company has been in operations since February 2004. The company has established solid reputation as a genomics service provider to academic, government and industrial research groups and institutions. Several papers have been published in leading scientific journals, based on the genomic services provided by MOgene. Company’s management and employees have a vast range of expertise and experience.